Multiple Dose Study for a New Medication to Potentially Treat Liver Diseases
← catalyst calendarNCT06891365 · readout in 418 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
48estimated
Sites
1
Country
United Kingdom
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-12 | actual | When the study began enrolling |
| Primary completion | 2027-10-11 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-11-15 | estimated | The whole study's end, after follow-up |
| First posted | 2025-03-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Healthy Volunteers
- Hepatic Steatosis
Interventions
- Drug: NNC0581-0001
- Drug: Placebo (NNC0581-0001)
Primary outcome
what the primary-completion date above is the date OFNumber of treatment emergent adverse events (TEAEs)
measured From 1st dose (day 1) until completion of the end of study visit at week 52
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed